BPC-157 vs TB-500

Overview

BPC-157 and TB-500 are both marketed for tissue repair and recovery, but neither is approved by any regulatory agency. Both lack rigorous human clinical trial data.

Evidence Comparison

Aspect	BPC-157	TB-500
Evidence Level	Low	Moderate
Human RCTs	1-2 (limited)	0 for TB-500 specifically
Primary Research	Single Croatian group	Extrapolated from Tβ4
Independent Replication	Limited	Limited

Mechanism Comparison

Aspect	BPC-157	TB-500
Origin	Gastric juice protein	Thymosin beta-4 fragment
Proposed Action	VEGF, NO system	Actin sequestration
Target Tissues	GI, tendon, muscle	Multiple tissues

Preclinical Data

BPC-157

• Primarily from one research group
• Rodent models show tendon, muscle, GI effects
• Mechanism studies ongoing

TB-500

• Parent compound (Tβ4) has more research
• Fragment (TB-500) less studied
• Wound healing effects proposed

Regulatory Status

Aspect	BPC-157	TB-500
FDA Status	Not approved	Not approved
WADA Status	Prohibited	Prohibited
Development	No active pharma program	Tβ4 has some development

Safety Concerns

Both peptides:

• Lack comprehensive human safety data
• Are sold through unregulated sources
• Have unknown long-term effects
• May have quality/purity issues

Key Differences

Factor	BPC-157	TB-500
GI Focus	Strong (origin)	Less emphasized
Systemic Claims	Broader	Wound/injury focused
Parent Research	BPC protein	Thymosin beta-4

Summary

Neither peptide has sufficient evidence for clinical use:

• BPC-157: More published preclinical data but from limited sources
• TB-500: Relies on extrapolation from thymosin beta-4 research
• Both are prohibited in sport
• Both lack regulatory approval

---

This comparison is for educational purposes only. Neither peptide is approved by regulatory agencies.